
Join to view full profile
20 York StNew Haven, CT 06510
Phone+1 203-688-4242
Dr. Ishizuka is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2019
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2014 - 2015
Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 2013 - 2014
Harvard Medical SchoolClass of 2012
Certifications & Licensure
CT State Medical License 2020 - 2027
MA State Medical License 2016 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma.Tyler J Aprati, Chi-Ping Day, Daniel Lee, Alexander Pan, Justin Jee
Biorxiv. 2025-01-27 - 2 citationsReal world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era.Daniel Y Lee, Alexander Pan, Maxim Yaskolko, Michael Chiorazzi, Aarti Bhatia
Frontiers in Oncology. 2025-01-01 - 2 citationsCauses of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.Daniel Y Lee, Madeline McNamara, Alexander Yang, Maxim Yaskolko, Harriet Kluger
Pigment Cell & Melanoma Research. 2024-11-01
Press Mentions
Immunotherapy: Balancing Cancer Treatment Benefits and RisksMay 2nd, 2025
Yale Study Highlights Unmet Needs for Patients with Melanoma Who Progress or Relapse After Immunotherapy TreatmentAugust 30th, 2024
Grant Support
- Targeting dsRNA sensing and ADAR1 in melanomaYALE UNIVERSITY2024–2029
- Multiplexed, Continuous Reporting of Gene Expression via CRISPR-mediated Transcriptional ActivationYALE UNIVERSITY2024–2027
- Triggering Innate Immunity in Tumor Cells to Overcome Resistance to ImmunotherapyYALE UNIVERSITY2020–2025
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









